Skip to main content
. 2012 Mar 6;14(2):252–261. doi: 10.1208/s12248-012-9342-9

Fig. 6.

Fig. 6

Plasma concentrations of bevacizumab labeled with IRDye 800CW after SC (a) and IV (b) administration of 0.45 mg/kg doses in SKH-1 mice. Concentrations were determined by fluorescence and ELISA measurements. Data are presented as mean ± SD, n = 3